Dr. Paik is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Brigham Womens Hospital
75 Francis St Renal Div MRB4
Boston, MA 02115Phone+1 617-732-6383
Education & Training
Brigham and Women's Hospital/Massachusetts General HospitalFellowship, Nephrology, 2007 - 2011
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2004 - 2007- Icahn School of Medicine at Mount SinaiClass of 2004
Certifications & Licensure
MA State Medical License 2007 - 2025
NY State Medical License 2005 - 2007
Publications & Presentations
PubMed
- 1 citationsEmpagliflozin and the Risk of Retinopathy in Patients With Type 2 Diabetes.Helen Tesfaye, Julie M Paik, Miin Roh, Phyo T Htoo, Heidi Zakoul
JAMA Ophthalmology. 2024-12-05 - Fracture in Association with Anticoagulant Therapy in Patients with Chronic Kidney Disease and Atrial Fibrillation.Nazleen F Khan, Seoyoung C Kim, Su Been Lee, Katsiaryna Bykov, Julie M Paik
Clinical Journal of the American Society of Nephrology. 2024-11-19 - Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort study.Wajd Alkabbani, Karine Suissa, Kristine D Gu, Sara J Cromer, Julie M Paik
BMJ. 2024-10-22
Press Mentions
SGLT2 Inhibitors vs DPP4 Inhibitors Lower Hyperkalemia Risk in CKD+T2D CasesAugust 15th, 2024- Empagliflozin May Reduce Stone RiskNovember 5th, 2022
- SGLT2 Inhibitor Use Rising in Patients with DKDAugust 23rd, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
